Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
The Ehave Inc. (EHVVF) news feed on Stock Titan aggregates company communications and related updates that describe its evolution into an applied artificial intelligence platform operator. Recent press releases highlight Ehave’s acquisition of AIHeadHunter, an AI-powered recruitment platform designed to automate and streamline executive search and talent sourcing through advanced data analysis. These announcements provide insight into how Ehave is repositioning itself around data-driven technology assets and AI-enabled business models.
News linked to Ehave also frequently references its subsidiary AIBotics, Inc. (traded as AIBT), which is described as a developer and manager of AI- and robotics-enhanced technologies. AIBotics press releases cover topics such as the development and pilot deployment of the Phill Robot™ massage robot, the Milkyway smart refrigerator, and partnerships aimed at distributing service robots in markets like Israel and Jamaica. These items illustrate how Ehave’s subsidiary is working with AI, robotics, and agentic AI concepts to build products and platforms for wellness, service environments, and intelligent automation.
Investors and observers using this news page can review how Ehave describes its strategic realignment, including its focus on incubating scalable AI platforms and structuring transactions to support that shift. Coverage includes acquisition terms for AIHeadHunter, descriptions of the technology licensed for that platform, and statements about Ehave’s plans to fund and launch enterprise pilots. For AIBotics, the news flow includes product development milestones, collaboration agreements for UI/UX and operating platforms, and early commercialization efforts such as pilot programs in fitness and wellness facilities.
By following the EHVVF news page, readers can see how Ehave communicates its progress on AIHeadHunter, its relationship with AIBotics, and its broader approach to applied AI and robotics. The articles provide context on the company’s stated objectives, the markets it is targeting through its platforms, and the partnerships it reports as part of its growth plans.
Ehave, a provider of digital therapeutics for mental health, announced its sponsorship of the upcoming PsyTech Summit, taking place virtually on July 19-20, 2021. The company aims to promote its KetaDASH platform, a HIPAA-compliant cloud solution for at-home ketamine infusion therapy. The summit will explore critical psychedelic topics featuring notable industry speakers. Ehave emphasizes the significance of this event for enhancing visibility and engagement in the psychedelic sector, particularly as it rolls out innovative therapeutic solutions.
Ehave, Inc. announces the addition of Dr. Muneer A. Ali to its Medical Advisory Board, effective July 1, 2021. Dr. Ali, a board-certified clinical psychiatrist and Associate Medical Director at Amen Clinics, will provide guidance on human trials for cognitive and psychedelic therapies. His expertise includes ADHD, anxiety disorders, and substance use disorders. Ehave's Chief Medical Officer highlighted Dr. Ali's invaluable insights as the company progresses in human trials. Ehave focuses on digital therapeutics to improve mental health care, leveraging blockchain technology through its flagship product, the Ehave Dashboard.
Ehave, Inc. (OTC Pink: EHVVF) has appointed Dr. Jeffrey D. Kamlet as its new Chief Medical Officer, bringing over 30 years of experience in internal medicine and addiction. This strategic hire aims to deepen clinical expertise and advance clinical studies on I.V. Ketamine treatments targeting anxiety, depression, and PTSD. Dr. Kamlet, recognized for his work in ibogaine treatment and cardiac safety, expressed enthusiasm for joining Ehave's mission to enhance mental health treatment options. Ehave continues to focus on innovative therapeutics in the mental health sector.
Ehave, Inc. (EHVVF) introduces its Medical and Vaccine Passport aimed at streamlining Covid-19 vaccination verification for small businesses. This tool enables individuals to securely manage health records and vaccination status, providing convenience as mask mandates relax. With over 150 million potential users, the upcoming Ehave Mobile App will facilitate access to electronic health records (EHRs) and billing data. The app aims to empower users to combine their health data from various sources, supporting patient-generated data to enhance healthcare engagement.
Ehave, Inc. (EHVVF) announces a licensing agreement with Health Wizz to enhance its digital health dashboard by integrating medical records management capabilities. This partnership will enable users to securely share their personal health data while ensuring HIPAA compliance. The Health Wizz mobile app, coupled with blockchain technology, aims to empower individuals to manage their health data efficiently. The global market for Electronic Health Records (EHR) is projected to reach $33.41 billion by 2025, highlighting the significance of this advancement in patient care.
Ehave, Inc. (EHVVF) has launched its KetaDASH subsidiary, introducing a HIPAA-compliant platform for at-home ketamine treatments for anxiety, depression, and PTSD.
The service aims to facilitate access to IV ketamine therapy through partnerships with clinics and healthcare providers. With studies showing that up to 85% of ketamine users experience mental health improvements, this initiative addresses the growing demand for alternative mental health solutions.
CEO Ben Kaplan emphasized the importance of providing compassionate care in a home setting.
Ehave, Inc. (EHVVF) announced the upcoming launch of KetaDASH, a groundbreaking intravenous home delivery service for ketamine therapy, expected to begin by the end of Q2 2021. This platform enables licensed clinics to treat homebound patients, potentially increasing revenue opportunities. The company has secured liability coverage and is negotiating franchising across the U.S.
Ketamine, used for pain relief, is also being studied for depression treatment. KetaDASH offers a personalized approach, connecting patients with skilled nurses for at-home care.
Ehave, Inc. (EHVVF) announced a partnership with Brain Scientific Inc. to conduct brain mapping ketamine clinical trials aimed at treating chronic pain, depression, PTSD, and other mental disorders. The trial will enroll 35 patients and start in the second half of 2021, focusing on establishing a correlation between ketamine treatment and patient improvements. Ehave aims to leverage data and AI for better mental health solutions. The trial’s primary goal is to assess safety and tolerability, with updates promised throughout the clinical process.
Ehave, Inc. (EHVVF) is collaborating with Silo Wellness Inc. for a clinical study on the effects of psilocybin during wellness retreats in Jamaica. This study aims to explore the neurobiological impacts of psychedelic substances on mental health disorders such as depression, anxiety, and ADHD. Utilizing advanced EEG technologies, including Brain Scientific's NeuroCap, Ehave will collect data on brain activity before, during, and after psilocybin administration. This partnership highlights Ehave's commitment to enhancing therapeutic approaches through data-driven insights.
Ehave, Inc. (EHVVF), a provider of digital therapeutics in the psychedelic and mental health sectors, announced that its CEO, Benjamin Kaplan, will appear on the Psychedelic Spotlight segment of New to the Street. The segment will air on NewsMax on March 14th at 10:00 AM EST and on Fox Business on March 15th at 7:30 PM EST. This appearance is an opportunity for shareholders to gain insight into Ehave and the psychedelic sector. Ehave focuses on improving care for brain disorders through innovations like the Ehave Telemetry Portal.
FAQ
What is the current stock price of Ehave (EHVVF)?
What is the market cap of Ehave (EHVVF)?
